Navigation Links
Enzon to Present Preclinical Data From PEG-SN38 and PEGylation,Technology Studies at AACR Meeting

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Apr 12, 2007 - Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) announced today that four posters containing preclinical data will be presented at the 2007 Annual Meeting of the American Association for Cancer Research (AACR) to be held from April 14 - 18, 2007 in Los Angeles, CA.

Details of the presentations are as follows:

-- Abstract #1494: EZN-2208, a novel polyethyleneglycol-SN38 conjugate, has potent antitumor activity in a panel of human tumor xenografts (Poster displayed on Sunday, April 15, 2007, 1:00 PM - 5:00 PM, PT, Poster Section 30, Poster Board 8.)

-- Abstract #1496: EZN-2208, a novel poly ethylene glycol-SN38 conjugate, improves pharmacological properties of SN38 in mice and rats. (Poster displayed on Sunday, April 15, 2007, 1:00 PM - 5:00 PM, PT, Poster Section 30, Poster Board 10.)

-- Abstract #4731: Customized positive PEG linkers for the delivery of antisense molecules (Poster displayed on Tuesday, April 17, 2007, 1:00 PM - 5:00 PM, PT, Poster Section 25, Poster Board 14.)

-- Abstract #4726: In vitro and in vivo evaluation of PEGylated anti-Bcl2 siRNA conjugates in a Bcl-2 over-expressing lung cancer model (Poster displayed on Tuesday, April 17, 2007, 1:00 PM - 5:00 PM, PT, Poster Section 25, Poster Board 9.)

About Enzon

Enzon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development, manufacturing, and commercialization of important medicines for patients with cancer and other life-threatening conditions. Enzon has a portfolio of four marketed products, Oncaspar(R), DepoCyt(R), Abelcet(R) and Adagen(R). The Company's drug development programs utilize several cutting-edge approaches, including its industry-leading PEGylation technology platform used to create product candidates with benefits such as reduced dosing frequency and less toxicity. Enzon's PEGylation technology was used to develop two o f its products, Oncaspar and Adagen, and has created a royalty revenue stream from licensing partnerships for other products developed using the technology. Enzon also engages in contract manufacturing for several pharmaceutical companies to broaden the Company's revenue base. Further information about Enzon and this press release can be found on the Company's web site at www.enzon.com.

Forward Looking Statements

There are forward-looking statements contained herein, which can be identified by the use of forward-looking terminology such as the words "believes," "expects," "may," "will," "should", "potential," "anticipates," "plans" or "intends" and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from the future results, events or developments indicated in such forward-looking statements. Such factors include, but are not limited to the timing, success and cost of clinical studies; the ability to obtain regulatory approval of products, market acceptance of, and continuing demand for, Enzon's products and the impact of competitive products and pricing. A more detailed discussion of these and other factors that could affect results is contained in our filings with the U.S. Securities and Exchange Commission, including our annual report on Form 10-K for the 12-month period ended December 31, 2006. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. No assurance can be given that the future results covered by the forward-looking statements will be achieved. All information in this press release is as of the date of this press release and Enzon does not intend to update this information.

Contact

Enzon Pharmaceuticals, Inc.
Craig Tooman, 908-541-8777
EVP, Finance and Chief Financial Officer


'"/>




Related medicine technology :

1. The Past, Present and Future of HLA Typing
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
10. Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth Conference and Attend Pacific Growth Equities Conference
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... , May 24, 2016 ... Markt gebracht, die es Ärzten erlaubt, ihre Expertise ... behandeln: MDLinking kombiniert Live Streaming mit einer Instant-Messaging-Funktion ... zu kommunizieren. Mediziner in Europa, Afrika, Asien und ... bereits für die Plattform registriert. Information ...
(Date:5/24/2016)... Nev. , May 24, 2016  Diana Russell ... "eats" her organs from the inside out.  This disease ... completely dependent on her children and grandchildren to leave ... her wheelchair, Diana,s family cannot haul the wheelchair.  So ... in the car, and Diana is left to wait ...
(Date:5/24/2016)... 24, 2016  Joe Marziani has joined VMS BioMarketing as senior vice president of ... In his new role, Marziani will lead the company,s business development and sales team, ... outcomes. Photo - http://photos.prnewswire.com/prnh/20160523/371089 ... ... ...
Breaking Medicine Technology:
(Date:5/25/2016)... ... May 25, 2016 , ... Dr. Travis Schwarz is an ... 8618 Mexico Road, O’Fallon, MO 63366. He serves patients of all ages with a ... . Dr. Schwarz’s success is reflected in the superior patient reviews that he has ...
(Date:5/25/2016)... ... May 25, 2016 , ... Today Omega Institute, a leading ... 11 innovative workshops and training opportunities in the growing field of yoga ... individuals who are dealing with specific health issues—including injuries, illnesses, and temporary or chronic ...
(Date:5/25/2016)... ... ... Cheryl Bowker of Bowker Insurance Group has been presented with one of the ... ran one of Allstate’s most successful agencies for 48 years, but it was his ... award named for him is not given every year, but only when an agency ...
(Date:5/25/2016)... ... 25, 2016 , ... The Global Wellness Summit (GWS) today announced that its ... of Europe, a continent that pioneered the medical/wellness concept for the world. , Delegates ... medical wellness, including Henri Chenot, Founder of the Chenot Group, which operates wellness centers ...
(Date:5/25/2016)... ... May 25, 2016 , ... TransactRx announces the release of ... medical service claims by Pharmacy Benefit Managers that were submitted by Retail Clinics ... TransactRx Cross Benefit Clearinghouse receives standard professional medical claims submitted from the retail ...
Breaking Medicine News(10 mins):